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Abstract We report on three patients (two siblings and one
unrelated) presenting in infancy with progressive muscle
weakness and paralysis of the diaphragm. Metabolic studies
revealed a profile of plasma acylcarnitines and urine organic
acids suggestive of a mild form of the multiple acyl-CoA
dehydrogenation defect (MADD, ethylmalonic/adipic acid
syndrome). Subsequently, a profound flavin deficiency in
spite of a normal dietary riboflavin intake was established in
the plasma of all three children, suggesting a riboflavin
transporter defect. Genetic analysis of these patients demon-
strated mutations in the C20orf54 gene which encodes the
human homolog of a rat riboflavin transporter. This gene was
recently implicated in the Brown-Vialetto-Van Laere syn-
drome, a rare neurological disorder which may either present
in infancy with neurological deterioration with hypotonia,
respiratory insufficiency and early death, or later in life with
deafness and progressive ponto-bulbar palsy. Supplementa-
tion of riboflavin rapidly improved the clinical symptoms as
well as the biochemical abnormalities in our patients,
demonstrating that high dose riboflavin is a potential
treatment for the Brown-Vialetto-Van Laere syndrome as
well as for the Fazio Londe syndrome which is considered to
be the same disease entity without the deafness.
Introduction
Brown-Vialetto-van Laere syndrome (MIM 211530), is a
rare neurological disorder which may present in infancy with
a devastating neurological deterioration with hypotonia,
respiratory insufficiency and early death, or later in life with
deafness and progressive ponto-bulbar palsy (Green et al.
2010; Sathasivam 2008). The same clinical presentation
without deafness is also known as Fazio Londe disease
(MIM 211500). Both are now considered to be a single
disease entity (Dipti et al. 2005).
The multiple acyl-CoA dehydrogenation defect (MADD) is
an inherited defect of mitochondrial fatty acid beta-oxidation
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and branched-chain amino acid catabolism (MIM231680).
This disorder is characterized by themalfunctioning of an array
of dehydrogenation reactions caused by the absence of either
electron transfer flavoprotein (ETF) or electron transfer
flavoprotein oxidoreductase (ETFDH). The electrons which
are liberated in the dehydrogenation reactions are primarily
captured by flavin adenine dinucleotide (FAD), a metabolite of
the vitamin riboflavin. MADDmay present at any age, varying
from a lethal neonatal form and an infantile form characterized
by hazardous hypoketotic hypoglycaemia (Rhead et al. 1987)
to relatively mild adult lipid storage myopathy (Antozzi et al.
1994). Riboflavin responsive forms of MADD are usually the
consequence of a defective ETFDH (Olsen et al. 2007).
We present two siblings and one unrelated patient,
presenting in infancy with progressive muscle weakness
and paralysis of the diaphragm, later recognized as Fazio
Londe and Brown-Vialetto-van Laere syndrome. Our
patients demonstrated abnormalities on metabolic evalua-
tion mimicking mild MADD and were found to be severely
flavin deficient. Riboflavin therapy resulted in a rapid
clinical and biochemical improvement.
Patients and methods
Patient 1
A 6month old boy, the first child of healthy parents, presented
with a short history of progressive muscle weakness followed
by life threatening apnoeic spells necessitating artificial
ventilation. Neurological examination revealed generalized
muscle weakness with a severe head lag. A complete
diaphragmatic paralysis was detected on ultrasound. Spinal
muscular atrophy (SMA) and SMA with respiratory distress
(SMARD) were excluded by genetic testing. Muscle histol-
ogy at the age of 7 months demonstrated unclassified
myopathic abnormalities. Biochemical analysis of the mito-
chondrial respiratory chain in fresh muscle tissue gave
inconclusive results. Metabolic studies revealed abnormal
concentrations of short- and medium-chain plasma acylcarni-
tines and a urine organic acid profile was suggestive of
MADD (Tables 1 and 2). Because of the possibility of
riboflavin-responsiveness (Olsen et al. 2007), the patient was
treated with high dose oral riboflavin (vitamin B2, 10 mg/kg
body weight/day). The MADD associated metabolic abnor-
malities disappeared within days. Cessation of riboflavin
supplementation resulted in a recurrence of the abnormal
metabolic profile in spite of a normal dietary riboflavin
intake, and riboflavin medication was restarted. Classical
MADD was ruled out by sequence analysis of the ETFDH,
ETFA and ETFB genes. The biochemical profile, absence of
urine thiosulfate and sulfo(thio)cysteine (Duran et al. 1997)
argued against an ethylmalonic syndrome (ETHE) (Tiranti et
al. 2009). Therefore we hypothesized a decreased availability
of flavin adenine dinucleotide (FAD), the cofactor of
MADD, due to defective uptake, synthesis or transport, to
be the underlying cause of the disease.
A tracheotomy was placed and the boy’s muscle tone
slowly improved over the next month. He was able to walk
independently at the age of 22 months. As the diaphrag-
matic paralysis persisted, he needed nightly ventilation until
the age of 41 months. Recently, the clinical diagnosis of
Fazio Londe Syndrome was made. He is currently
46 months old, his cognitive development is fully normal
and he demonstrates no further cranial nerve palsy.
Patient 2
Recently, the 3 months-old sister of patient 1 presented with
failure to thrive and generalized axial muscle weakness.
Based on the results of the additional studies in her brother,
flavin deficiency was suspected, subsequently confirmed by
Table 1 Plasma acylcarnitines (μmol/L) in patient, 2, and 3 compared to a MADD patient, a patient with the ethylmalonic acid syndrome, and
healthy controls. Bold values are outside normal range
Pat 1 before riboflavin Pat 2 before riboflavin Pat 3 at start of treatment MADD ETHE Controls
C0 18.3 35.1 37.6 4.2 35.4 22–55
C2 3.2 4.0 0.74 1.9 5.1 3.4–13
C4 0.65 2.97 0.43 8.55 2.07 0.07–0.58
C5 0.29 1.99 0.91 0.31 0.32 0.04–0.22
C6 0.27 0.87 0.02 0.14 0.05 0.02–0.12
C8 0.18 0.70 0.53 0.25 0.04 0.04–0.22
C10 0.25 0.86 0.77 0.49 0.06 0.04–0.30
C12 0.15 0.44 0.64 0.49 0.05 0.04-0.12
C14 0.14 0.23 0.46 0.39 <0.08
C16 0.19 0.19 0.32 0.37 0.09 0.06–0.24
C18:1 0.16 0.13 0.42 0.53 0.16 0.06–0.28
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the analysis of plasma flavins and acylcarnitines, and
treatment with riboflavin (10 mg/kg body weight /day) was
started. This resulted in normalization of her muscle tone
within 7 days and a rapid catch-up growth. Sensorineural
hearing loss was excluded by brainstem evoked response
audiometry. Therefore, the clinical diagnosis of Fazio Londe
Syndrome was made. After 3 months of riboflavin supple-
mentation her growth and development are normal.
Patient 3
A now 7 year old girl, second child of healthy parents,
demonstrated feeding problems and a slow motor develop-
ment since birth. At the age of 5 months she had generalized
weakness, more pronounced in distal than proximal muscle
groups, and developed respiratory insufficiency necessitating
artificial ventilation due to diaphragmatic paralysis. Further-
more, she was found to have a severe sensorineural hearing
loss. SMA and SMARD were excluded by genetic testing.
Muscle histology at the age of one year showed slight
predominance of type 1 fibers without type grouping.
Biochemical analysis of the mitochondrial respiratory chain
in muscle tissue was inconclusive.
At the age of 6 months, metabolic studies revealed an
acylcarnitine profile suggestive of MADD (Table 1). A fat
restricted diet and supplementation with carnitine (50 mg/
kg / day), riboflavin (10 mg/kg /day) and glycine and 3-
hydroxybutyrate according to the publication by Van Hove
et al. (2003) were started. Her muscle strength improved
and from the age of 2 years artificial ventilation was only
necessary during sleep. Cognitive development was normal.
Classical MADD was ruled out by enzymatic testing in
fibroblasts and mutation analysis of the ETFDH, ETFA and
ETFB genes. Following the normalization of the acylcarnitine
profiles, the fat restriction was gradually discontinued and the
glycine, 3-hydroxybutyrate and carnitine supplementations
were stopped without problems. However, withdrawal of
riboflavin at the age of 4 years resulted in a rapid clinical
deterioration with vomiting, progressive fatigue, and eleva-
tions of lactate, liver enzymes and CK. The acylcarnitine
profile became abnormal again. Reintroduction of riboflavin
(50 mg b.i.d.) resulted in clinical improvement and normal-
ization of the biochemical abnormalities. Sequence analysis of
the mitochondrial FAD transporter (Spaan et al. 2005) was
performed on suspicion of a possible mitochondrial ribofla-
vin transporter defect, but showed no abnormalities.
After reintroduction of riboflavin supplementation the
patient had a stable clinical course. She walked with a foot
drop and attended a school for hearing impaired children. The
parents gradually decreased the dose of riboflavin to 10 mg b.
i.d. because they suspected gastrointestinal side effects of the
high doses of riboflavin. However, after 5 years she developed
palsies of the 7th and 12th cranial nerves, and became
wheelchair bound. Furthermore, following a lower respira-
tory tract infection at the age of 6.5 years she became once
again completely ventilator dependent, and her muscle
strength slowly deteriorated. Only recently, the clinical
diagnosis of Brown-Violetto-Van Laere syndrome was
confirmed. The riboflavin dose was increased to 50 mgt.i.d.,
thus far without improvement of her symptoms.
Methods
Selective screening for inborn errors of metabolism was
performed by standard techniques including analysis of organic
acids in urine and acylcarnitines in plasma. Plasma riboflavin,
flavin mononucleotide (FMN) and FAD concentrations were
measured by high-performance liquid chromatography using
fluorescence detection of the analytes according to the
method of Capo-chichi et al. (2000) with minor modifications.
Because plasma flavins were deficient in all three patients
despite a normal intake, we suspected a defect in intestinal
riboflavin uptake and we therefore performed mutation
analysis of the C20orf54 gene. The protein encoded by this
gene is highly similar to the rat rRFT2 protein, which has
been shown to be the transporter of riboflavin in the small
intestine (Yamamoto et al. 2009). Mutation analysis of the
gene was performed by sequencing all exons plus flanking
intronic sequences amplified from genomic DNA extracted
from the patients’ cells. Confirmation of the mutation in the
parental genes was performed in genomic DNA extracted
from blood cells.
Fibroblast fatty acid oxidation studies were carried out in
patients 1 and 3 by incubating the cells with U-13C palmitate
Pat 1 before riboflavin MADD ETHE Controls
EMA 62 2648 48 <15
Glutarate 1 19986 1 <15
Adipate 70 5207 2 2–26
2-OH-glutarate 106 832 19 11–51
Suberate 26 764 1 <15
Hexanoylglycine + ++ –
Isovalerylglycine + ++ +
Table 2 Urine organic acids
(mmol/mol creat) in patient 1
compared to a MADD patient, a
patient with the ethylmalonic
acid syndrome, and healthy
controls
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for 96 hours followed by the analysis of acylcarnitines in
the supernatant (Ventura et al. 1999).
After the diagnosis had been established, the acylcarnitine
profiles of the newborn screening bloodspots of patients 1
and 2 were evaluated by standard ESI-tandem mass
spectrometric analysis. The newborn sample of patient 3
was no longer available.
Results
The initial diagnostic work-up of patient 1 included an
analysis of plasma acylcarnitines and urine organic acids
(Tables 1 and 2). A moderate accumulation of short and
medium-chain acylcarnitines was observed. The long-chain
acylcarnitines were normal. The profiles observed in
patients 2 and 3 were similar but differed somewhat in the
levels of the long-chain acylcarnitines, demonstrating the
biochemical variability of this defect. The acylcarnitine
profiles of the newborn screening bloodspots of patients 1
and 2 were normal (not shown), which demonstrates that
newborn screening for a riboflavin transporter by this
method is not feasible.
For comparison, plasma of a patient with an ETHE defect
was also investigated, demonstrating an accumulation of
short-chain acylcarnitines only (Table 1). Finally, plasma of
an infantile patient with hypoketotic hypoglycaemic MADD
resulting from a homozygous mutation of the ETFDH gene
showed increased levels of all characteristic short-, medium-,
and long-chain acylcarnitines as well as glutarylcarnitine.
Glutarylcarnitine was normal in both the riboflavin trans-
porter patients and the ETHE patient (Table 1). The C4
carnitine consisted mainly of the isobutyrylcarnitine, point-
ing to a considerable vulnerability of Acad 8 in all con-
ditions described here.
Organic acid analysis of the urine of patient 1 demon-
strated a pattern resembling that of mild MADD (Table 2).
Short and branched chain acylglycines were clearly
elevated as was the D-2-hydroxyglutaric acid. The ETHE
patient had a comparable excretion pattern, although
hexanoyl-glycine appeared to be normal. Patient 2 and 3
were not investigated. Neither the riboflavin transporter
patient nor the ETHE patient had an increased urine glutaric
acid, in contrast to the ETFDH patient (Table 3).
The fibroblast fatty acid oxidation studies in patients 1
and 3 revealed a normal profile of acylcarnitines, in sharp
contrast to the results obtained in the ETFDH patient,
showing accumulation of all C4-C16 intermediates.
Concentrations of riboflavin, FMN and FAD in plasma
before treatment revealed a deficiency of all flavins in
patients 1 and 2 (Table 3) whereas patient 3 had markedly
decreased levels of FMN and FAD. Riboflavin levels
normalized within weeks after the start of riboflavin
supplementation. Cessation of supplementation in patients
1 and 3 resulted in rapid recurrence of the deficient state.
Plasma flavins of the mother of patients 1 and 2 were normal.
Patient 1 and 2 were found to be homozygous for a
pathogenic splice acceptor site mutation inC20orf54: c.1198-
2A>C which is most probably pathogenic as it concerns a
mutation of an invariant nucleotide of a splice acceptor site
and thus will lead to incorrect mRNA splicing. The parents,
second cousins, were heterozygous for this mutation.
Patient 3 was found to be heterozygous for two mutations
in the C20orf54 gene: c.49T>C (p.W17R) and c.639C>G
(p.Y213X). The latter mutation was also identified by
Green et al. (2010). The c.49T>C mutation affects a
tryptophan at position 17, which is highly conserved in
orthologs of different species.
Discussion
Riboflavin is the precursor of FAD, which acts as an electron
acceptor in a number of acyl-CoA dehydrogenation reactions
involved in mitochondrial fatty acid oxidation and branched-
chain amino acid catabolism (Gregersen et al. 2008). An
inherited or acquired deficiency of riboflavin will therefore
mimic the biochemical presentation observed in classical
MADD, which was indeed observed in a riboflavin-deficient
rat (Goodman 1981). The biochemical abnormalities observed
in our patients are reminiscent of the mild forms of MADD,
originally described as ethylmalonic/adipic aciduria (Tanaka et
Table 3 Plasma flavin values in patients 1, 2,and 3 before and after the start of riboflavin therapy
Riboflavin (nmol/l) FMN (nmol/l) FAD (nmol/l)
Controls (mean +/- 2 SD) (n=43, ages 0–35 y) 3.9–49 2.8–11.4 46–114
Patient 1 before treatment 1.4 1.7 31
Patient 1 2 weeks after start therapy 18.5 2.1 100
Patient 2 before treatment <1 <1 30
Patient 2 4 weeks after start treatment 46.0 4.0 70
Patient 3 at start of treatment 7.6 <1 24.5
Patient 3 with supplementation 12.3 8.3 105
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al. 1977). Our data suggest that the short-chain and medium-
chain acyl-CoA dehydrogenases are more vulnerable to the
shortage of the physiological electron acceptor than the long-
chain analogues. Similarly, glutaryl-CoA dehydrogenase was
only mildly affected, in contrast to the D-2 hydroxyglutarate
dehydrogenase.
Based on the profiles of acylcarnitines and organic acids
it is difficult to make the distinction between the riboflavin
transporter defect and the ETHE defect. Both conditions,
however, have their own diagnostic analytes, i.e., riboflavin
in the riboflavin transporter defect (Brown-Vialetto-Van
Laere / Fazio Londe syndrome) and thiosulfate and sulfo
(thio)cysteine in ETHE (Duran et al. 1997). Metabolic
studies in intact fibroblasts were normal in the transporter
defect cells, probably because the riboflavin in the cell
culture medium corrected the defect resulting in a normal
fatty acid oxidation. Likewise, maternal riboflavin supply is
the probable cause of the normal clinical condition of the
patients at birth and the fact that the acylcarnitines were
normal in the newborn blood spots of patients 1 and 2.
Riboflavin deficiency usually presents with different
clinical symptoms (Powers 2003), but neurological symp-
toms resolving with riboflavin supplementation have been
previously reported in a child with moderate riboflavin
deficiency (Leshner 1981). Although further pathophysio-
logical studies are needed to explain the clinical symptoms,
we demonstrate that the riboflavin deficiency in our patients
resulted from a defect in the riboflavin transporter, encoded
by the C20orf54 gene.
Remarkably, at the same time that we discovered the
molecular defects in our patients, causing a defective
intestinal riboflavin transport, Green et al. (2010) reported
the identification of mutations in the C20orf54 gene as the
cause of the Brown-Vialetto-Van Laere Syndrome (MIM
211530). Indeed, the clinical presentation of all three
patients is compatible with the diagnosis of Brown-
Vialetto-van Laere (patient 3) or the Fazio Londe (patients
1 and 2) syndrome. This implies that at least part of the
clinical signs and symptoms observed in these syndromes
are caused by a deficiency of riboflavin and subsequently
of FAD and FMN. The striking clinical and biochemical
improvement on riboflavin supplementation seen in our
patients strongly supports this hypothesis. We therefore
presume that riboflavin may be an effective therapy in the
Brown-Vialetto-Van Laere syndrome, at least in young
patients. Early treatment appears to be crucial as diaphrag-
matic paralysis may be irreversible. Furthermore, in spite of
the riboflavin supplementation since the age of 6 months,
patient three now, at age 7, demonstrates the neurological
deterioration frequently observed in untreated Brown-
Vialetto-Van Laere patients. This can be due to damage
which already occurred during the extended periods of low
FAD values probably present during the first 6 months of
life as well as around the age of four, or to periods of
limited riboflavin availability during intercurrent illnesses,
as she demonstrated clinical deterioration mostly during
periods of viral illness. On the other hand, it is possible that
riboflavin supplementation only shifts the clinical course of
the Brown-Vialetto-Van Laere / Fazio Londe syndrome to a
later presentation of the clinical symptoms. A long term
follow up of a cohort of early treated children, and more
insight in the pathophysiology is warranted.
Finally, our results demonstrate that selective metabolic
screening, including acylcarnitine profiling and organic
acid analysis of the urine, is warranted in all patients with
unexplained hypotonia and that plasma flavins should be
measured in patients with riboflavin responsive MADD in
whom sequencing of the relevant genes fails to detected a
mutation.
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